Real-world data from over 10 years in the TYSABRI® Observational Program: Long-term safety and effectiveness of natalizumab in relapsing-remitting multiple sclerosis patients - 27/03/19
Bienvenue sur EM-consulte, la référence des professionnels de santé.
L’accès au texte intégral de cet article nécessite un abonnement.
| pages | 2 |
| Iconographies | 0 |
| Vidéos | 0 |
| Autres | 0 |
Résumé |
Introduction |
The TYSABRI Observational Program (TOP) began>10 years ago to inform on long-term safety and effectiveness of natalizumab in relapsing-remitting multiple sclerosis (RRMS) patients in clinical practice.
Objectives |
Report an interim analysis of safety and effectiveness in patients with up to 10 years of natalizumab treatment in TOP, an open-label, multinational, prospective, observational study.
Patients and methods |
Annualised relapse rates (ARRs) for the year prior to starting natalizumab and on natalizumab (and≤84 days post discontinuation) were compared using a repeated Poisson model. Confirmed Expanded Disability Status Scale (EDSS) worsening, and improvement, while on natalizumab were estimated by Kaplan–Meier analysis. Serious adverse events (SAEs) were assessed at clinical visits.
Results |
As of November 2017, TOP included 6149 patients. ARR while on natalizumab was reduced by 89.4% (from 1.99 pre- natalizumab to 0.21 on natalizumab; P<.001). Similarly, for those with BL EDSS scores<3.0 or≥3.0, ARR decreased by 91.0% (P<.001) and 87.9% (P<.001), respectively. For those with 0, 1, or≥2 prior DMTs, ARRs were reduced by 92.7% (P<.001), 91.0% (P<.001), and 86.7% (P<.001), respectively.
Discussion |
At 10 years, cumulative probabilities of 24-week–confirmed EDSS worsening and improvement were 32.9% and 35.5%, respectively. Overall, 828 of 6149 patients (13.5%) experienced≥1 SAE (most commonly reported by system organ class: infections and infestations, 253 patients [4.1%]).
Conclusion |
This analysis reinforces the consistent effectiveness—particularly when used earlier in the disease and treatment course–and the established safety profile of natalizumab, now assessed over 10 years.
Le texte complet de cet article est disponible en PDF.Keywords : TOP, Real-world, Natalizumab
Plan
Vol 175 - N° S1
P. S101-S102 - avril 2019 Retour au numéro
Article précédent
- Delayed-release Dimethyl Fumarate demonstrates sustained efficacy over nine years in newly diagnosed patients with relapsing-remitting multiple Sclerosis
- Ralf Gold, Gavin Giovannoni, Theodore Phillips, Amit Bar-Or, Robert J. Fox, Chongshu Chen, Catherine Miller
- Natalizumab extended interval dosing (EID) is associated with a significant reduction in progressive multifocal leukoencephalopathy (PML) risk compared with standard interval dosing (SID) in the TOUCH® Prescribing Program
- Ryerson Lana Zhovtis, John Foley, Ih Chang, Ilya Kister, Gary Cutter, Ryan Metzger, Judith D. Goldberg, Xiaochun Li, Evan Riddle, Karen Smirnakis, Bei Yu, Zheng Ren, Christophe Hotermans, Pei-Ran Ho, Nolan Campbell
Bienvenue sur EM-consulte, la référence des professionnels de santé.
L’accès au texte intégral de cet article nécessite un abonnement.
Bienvenue sur EM-consulte, la référence des professionnels de santé.
L’achat d’article à l’unité est indisponible à l’heure actuelle.
Déjà abonné à cette revue ?